CordenPharma, a Basel, Switzerland-based contract development and manufacturing organization (CDMO), has broken ground on a more than $200 million expansion at its South Carolina facility in North Augusta.

The project will add 68,000 square feet of commercial manufacturing space and expand the site’s upstream peptide synthesis capabilities. The facility will support solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid production platforms from clinical development through commercial manufacturing.

The expansion will complement CordenPharma’s large-scale downstream peptide manufacturing operations in Colorado. The company expects its South Carolina and Colorado facilities to represent more than $1.4 billion in U.S. peptide manufacturing investment and said the South Carolina project will create more than 200 jobs.

The CDMO said the expanded network will provide dual-site manufacturing options and support technology transfer between facilities. The additional capacity is intended to support peptide APIs used in therapies for obesity, diabetes, cardiovascular disease, cancer, and other conditions.

Earlier this month, CordenPharma announced an €80 million (about $94 million) expansion of sterile injectable manufacturing at its Caponago, Italy, facility. That project includes a new 11,000-square-meter building, two aseptic fill-finish lines, and expanded packaging and analytical capacity, with total site capacity expected to reach up to 500 million sterile injectable units annually.